Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2011, Article ID 431718, 13 pages
http://dx.doi.org/10.4061/2011/431718
Review Article

EGF and TGF- 𝛽 1 Effects on Thyroid Function

1Department of Oncology and Experimental Medicine, University “G. d'Annunzio” Chieti-Pescara, 66013 Chieti, Italy
2Center of Excellence on Aging, Ce.S.I., “G. d'Annunzio” University Foundation, 66013 Chieti, Italy
3Department of Experimental Medicine and Department of Radiological Sciences Oncology and Anatomical Pathology, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy

Received 14 January 2011; Accepted 22 March 2011

Academic Editor: Guillermo Juvenal

Copyright © 2011 Gabriella Mincione et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Vassart and J. E. Dumont, “The thyrotropin receptor and the regulation of thyrocyte function and growth,” Endocrine Reviews, vol. 13, no. 3, pp. 596–611, 1992. View at Publisher · View at Google Scholar
  2. D. M. Kingsley, “The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms,” Genes and Development, vol. 8, no. 2, pp. 133–146, 1994. View at Google Scholar · View at Scopus
  3. S. E. Wang, A. Narasanna, M. Perez-Torres et al., “HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors,” Cancer Cell, vol. 10, no. 1, pp. 25–38, 2006. View at Publisher · View at Google Scholar · View at PubMed
  4. G. Colletta, A. M. Cirafici, and A. Di Carlo, “Dual effect of transforming growth factor beta on rat thyroid cells: inhibition of thyrotropin-induced proliferation and reduction of thyroid-specific differentiation markers,” Cancer Research, vol. 49, no. 13, pp. 3457–3462, 1989. View at Google Scholar
  5. L. M. Asmis, H. Gerber, J. Kaempf, and H. Studer, “Epidermal growth factor stimulates cell proliferation and inhibits iodide uptake of FRTL-5 cells in vitro,” Journal of Endocrinology, vol. 145, no. 3, pp. 513–520, 1995. View at Google Scholar
  6. J. Massaguè, S. W. Blain, and R. S. Lo, “TGFbeta signaling in growth control, cancer, and heritable disorders,” Cell, vol. 103, no. 2, pp. 295–309, 2000. View at Google Scholar · View at Scopus
  7. J. E. Dumont, C. Maenhaut, and F. Lamy, “Control of thyroid cell proliferation and goitrogenesis,” Trends in Endocrinology and Metabolism, vol. 3, no. 1, pp. 12–17, 1992. View at Publisher · View at Google Scholar
  8. A. M. Musti, V. M. Ursini, E. V. Avvedimento, V. Zimarino, and R. D. Lauro, “A cell type specific factor recognizes the rat thyroglobulin promoter,” Nucleic Acids Research, vol. 15, no. 20, pp. 8149–8166, 1987. View at Publisher · View at Google Scholar
  9. M. Zannini, V. Avantaggiato, E. Biffali et al., “TTF-2, a new forkhead protein, shows a temporal expression in the developing thyroid which is consistent with a role in controlling the onset of differentiation,” EMBO Journal, vol. 16, no. 11, pp. 3185–3197, 1997. View at Publisher · View at Google Scholar · View at PubMed
  10. M. Zannini, H. Francis-Lang, D. Plachov, and R. Di Lauro, “Pax-8, a paired domain-containing protein, binds to a sequence overlapping the recognition site of a homeodomain and activates transcription from two thyroid-specific promoters,” Molecular and Cellular Biology, vol. 12, no. 9, pp. 4230–4241, 1992. View at Google Scholar
  11. P. P. Roger, M. Taton, J. Van Sande, and J. E. Dumont, “Mitogenic effects of thyrotropin and adenosine 3',5'-monophosphate in differentiated normal human thyroid cells in vitro,” Journal of Clinical Endocrinology and Metabolism, vol. 66, no. 6, pp. 1158–1165, 1988. View at Google Scholar
  12. S. Filetti and B. Rapoport, “Autoregulation by iodine of thyroid protein synthesis: influence of iodine on amino acid transport in cultured thyroid cells,” Endocrinology, vol. 114, no. 4, pp. 1379–1385, 1984. View at Google Scholar
  13. B. Van Heuverswyn, A. Leriche, J. Van Sande, J. E. Dumont, and G. Vassart, “Transcriptional control of thyroglobulin gene expression by cyclic AMP,” FEBS Letters, vol. 188, no. 2, pp. 192–196, 1985. View at Google Scholar
  14. D. Tramontano, G. W. Cushing, A. C. Moses, and S. H. Ingbar, “Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves'-IgG,” Endocrinology, vol. 119, no. 2, pp. 940–942, 1986. View at Google Scholar · View at Scopus
  15. P. Santisteban, L. D. Kohn, and R. Di Lauro, “Thyroglobulin gene expression is regulated by insulin and insulin-like growth factor I, as well as thyrotropin, in FRTL-5 thyroid cells,” Journal of Biological Chemistry, vol. 262, no. 9, pp. 4048–4052, 1987. View at Google Scholar
  16. M. Saji, T. Akamizu, M. Sanchez et al., “Regulation of thyrotropin receptor gene expression in rat FRTL-5 thyroid cells,” Endocrinology, vol. 130, no. 1, pp. 520–533, 1992. View at Publisher · View at Google Scholar
  17. Y. Yarden and M. X. Sliwkowski, “Untangling the ErbB signalling network,” Nature Reviews Molecular Cell Biology, vol. 2, no. 2, pp. 127–137, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. R. Pinkas-Kramarski, L. Soussan, H. Waterman et al., “Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions,” EMBO Journal, vol. 15, no. 10, pp. 2452–2467, 1996. View at Google Scholar
  19. D. Graus-Porta, R. R. Beerli, J. M. Daly, and N. E. Hynes, “ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling,” EMBO Journal, vol. 16, no. 7, pp. 1647–1655, 1997. View at Publisher · View at Google Scholar · View at PubMed
  20. M. Alimandi, A. Romano, M. C. Curia et al., “Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas,” Oncogene, vol. 10, no. 9, pp. 1813–1821, 1995. View at Google Scholar
  21. S. V. Sharma, D. W. Bell, J. Settleman, and D. A. Haber, “Epidermal growth factor receptor mutations in lung cancer,” Nature Reviews Cancer, vol. 7, no. 3, pp. 169–181, 2007. View at Publisher · View at Google Scholar · View at PubMed
  22. D. S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno, “Epidermal growth factor-related peptides and their receptors in human malignancies,” Critical Reviews in Oncology/Hematology, vol. 19, no. 3, pp. 183–232, 1995. View at Publisher · View at Google Scholar
  23. R. Zandi, A. B. Larsen, P. Andersen, M.-T. Stockhausen, and H. S. Poulsen, “Mechanisms for oncogenic activation of the epidermal growth factor receptor,” Cellular Signalling, vol. 19, no. 10, pp. 2013–2023, 2007. View at Publisher · View at Google Scholar · View at PubMed
  24. D. K. Moscatello, M. Holgado-Madruga, A. K. Godwin et al., “Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors,” Cancer Research, vol. 55, no. 23, pp. 5536–5539, 1995. View at Google Scholar
  25. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire, “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987. View at Google Scholar
  26. J. W. Lee, Y. H. Soung, S. H. Seo et al., “Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas,” Clinical Cancer Research, vol. 12, no. 1, pp. 57–61, 2006. View at Publisher · View at Google Scholar · View at PubMed
  27. P. Stephens, C. Hunter, G. Bignell et al., “Lung cancer: intragenic ERBB2 kinase mutations in tumours,” Nature, vol. 431, no. 7008, pp. 525–526, 2004. View at Google Scholar
  28. H. Shigematsu, T. Takahashi, M. Nomura et al., “Somatic mutations of the HER2 kinase domain in lung adenocarcinomas,” Cancer Research, vol. 65, no. 5, pp. 1642–1646, 2005. View at Publisher · View at Google Scholar · View at PubMed
  29. R. Naidu, M. Yadav, S. Nair, and M. K. Kutty, “Expression of c-erbB3 protein in primary breast carcinomas,” British Journal of Cancer, vol. 78, no. 10, pp. 1385–1390, 1998. View at Google Scholar
  30. C. A. Maurer, H. Friess, B. Kretschmann et al., “Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2,” Human Pathology, vol. 29, no. 8, pp. 771–777, 1998. View at Publisher · View at Google Scholar
  31. M. Kobayashi, A. Iwamatsu, A. Shinohara-Kanda, S. Ihara, and Y. Fukui, “Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas,” Oncogene, vol. 22, no. 9, pp. 1294–1301, 2003. View at Publisher · View at Google Scholar · View at PubMed
  32. T. Rajkumar, G. W. H. Stamp, C. M. Hughes, and W. J. Gullick, “c-erbB3 protein expression in ovarian cancer,” Journal of Clinical Pathology, vol. 49, no. 4, pp. M199–M202, 1996. View at Google Scholar
  33. H. Friess, L. Wang, Z. Zhu et al., “Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas,” Annals of Surgery, vol. 230, no. 6, pp. 767–775, 1999. View at Publisher · View at Google Scholar
  34. T. Holbro, R. R. Beerli, F. Maurer, M. Koziczak, C. F. Barbas III, and N. E. Hynes, “The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8933–8938, 2003. View at Publisher · View at Google Scholar · View at PubMed
  35. T. T. Junttila, M. Sundvall, J. A. Määttä, and K. Elenius, “ErbB4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants,” Trends in Cardiovascular Medicine, vol. 10, no. 7, pp. 304–310, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. J. A. Määttä, M. Sundvall, T. T. Junttila et al., “Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth,” Molecular Biology of the Cell, vol. 17, no. 1, pp. 67–79, 2006. View at Publisher · View at Google Scholar · View at PubMed
  37. C. C. Lynch, T. Vargo-Gogola, M. D. Martin, B. Fingleton, H. C. Crawford, and L. M. Matrisian, “Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor,” Cancer Research, vol. 67, no. 14, pp. 6760–6767, 2007. View at Publisher · View at Google Scholar · View at PubMed
  38. R. S. Muraoka-Cook, L. S. Caskey, M. A. Sandahl et al., “Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1,” Molecular and Cellular Biology, vol. 26, no. 17, pp. 6412–6424, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. T. Hoelting, A. E. Siperstein, O. H. Clark, and Q.-Y. Duh, “Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo,” Journal of Clinical Endocrinology and Metabolism, vol. 79, no. 2, pp. 401–408, 1994. View at Publisher · View at Google Scholar
  40. B. F. van der Laan, J. L. Freeman, and S. L. Asa, “Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues,” Thyroid, vol. 5, no. 1, pp. 67–73, 1995. View at Google Scholar
  41. G. Bechtner, D. Schopohl, M. Rafferzeder, R. Gärtner, and U. Welsch, “Stimulation of thyroid cell proliferation by epidermal growth factor is different from cell growth induced by thyrotropin or insulin-like growth factor I,” European Journal of Endocrinology, vol. 134, no. 5, pp. 639–648, 1996. View at Google Scholar
  42. B. Gabler, T. Aicher, P. Heiss, and R. Senekowitsch-Schmidtke, “Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti-EGF-receptor antibody,” Anticancer Research, vol. 17, no. 4, pp. 3157–3159, 1997. View at Google Scholar
  43. Y. Mizukami, A. Nonomura, T. Hashimoto et al., “Immunohistochemical demonstration of epidermal growth factor and c-myc oncogene product in normal, benign and malignant thyroid tissues,” Histopathology, vol. 18, no. 1, pp. 11–18, 1991. View at Google Scholar
  44. V. Gorgoulis, D. Aninos, C. Priftis et al., “Expression of epidermal growth factor, transforming growth factor-alpha and epidermal growth factor receptor in thyroid tumors,” In Vivo, vol. 6, no. 3, pp. 291–296, 1992. View at Google Scholar
  45. R. Aasland, J. R. Lillehaug, R. Male, O. Josendal, J. E. Varhaug, and K. Kleppe, “Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB,” British Journal of Cancer, vol. 57, no. 4, pp. 358–363, 1988. View at Google Scholar · View at Scopus
  46. D. R. Haugen, L. A. Akslen, J. E. Verhaug, and J. R. Lillehaug, “Demonstration of a TGF-alpha-EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas,” International Journal of Cancer, vol. 55, no. 1, pp. 37–43, 1993. View at Google Scholar · View at Scopus
  47. G. Mincione, A. Piccirelli, D. Lazzereschi, D. S. Salomon, and G. Colletta, “Heregulin-dependent autocrine loop regulates growth of K-ras but not erbB-2 transformed rat thyroid epithelial cells,” Journal of Cellular Physiology, vol. 176, no. 2, pp. 383–391, 1998. View at Publisher · View at Google Scholar
  48. O. Fluge, L. A. Akslen, D. R. F. Haugen, J. E. Varhaug, and J. R. Lillehaug, “Expression of heregulins and associations with the ErbB family of tyrosine kinase receptors in papillary thyroid carcinomas,” International Journal of Cancer, vol. 87, no. 6, pp. 763–770, 2000. View at Publisher · View at Google Scholar
  49. J. D. Bergstrom, B. Westermark, and N.-E. Heldin, “Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells,” Experimental Cell Research, vol. 259, no. 1, pp. 293–299, 2000. View at Publisher · View at Google Scholar · View at PubMed
  50. B. Song, “Immunohistochemical demonstration of epidermal growth factor receptor and ceruloplasmin in thyroid diseases,” Acta Pathologica Japonica, vol. 41, no. 5, pp. 336–343, 1991. View at Google Scholar
  51. B. A. Schiff, A. B. McMurphy, S. A. Jasser et al., “Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer,” Clinical Cancer Research, vol. 10, no. 24, pp. 8594–8602, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. S. Hoffmann, S. Gläser, A. Wunderlich et al., “Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors-a novel antiproliferative/antiangiogenic strategy in thyroid cancer,” Langenbeck's Archives of Surgery, vol. 391, no. 6, pp. 589–596, 2006. View at Publisher · View at Google Scholar · View at PubMed
  53. L. A. Akslen, A. O. Myking, H. Salvesen, and J. E. Varhaug, “Prognostic impact of EGF-receptor in papillary thyroid carcinoma,” British Journal of Cancer, vol. 68, no. 4, pp. 808–812, 1993. View at Google Scholar
  54. U. Marti, C. Ruchti, J. Kämpf et al., “Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues,” Thyroid, vol. 11, no. 2, pp. 137–145, 2001. View at Google Scholar
  55. J. C. Utrilla, I. Martin-Lacave, M. V. San Martin, J. M. Fernandex-Santos, and H. Galera-Davidson, “Expression of c-erbB-2 oncoprotein in human thyroid tumours,” Histopathology, vol. 34, no. 1, pp. 60–65, 1999. View at Publisher · View at Google Scholar
  56. D. R. F. Haugen, L. A. Akslen, J. E. Varhaug, and J. R. Lillehaug, “Expression of c-erbB-2 protein in papillary thyroid carcinomas,” British Journal of Cancer, vol. 65, no. 6, pp. 832–837, 1992. View at Google Scholar
  57. T. Murakawa, H. Tsuda, T. Tanimoto, T. Tanabe, S. Kitahara, and O. Matsubara, “Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach,” Pathology International, vol. 55, no. 12, pp. 757–765, 2005. View at Publisher · View at Google Scholar · View at PubMed
  58. S. L. Sugg, S. Ezzat, L. Zheng, I. B. Rosen, J. L. Freeman, and S. L. Asa, “Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia,” Clinical Endocrinology, vol. 49, no. 5, pp. 629–637, 1998. View at Publisher · View at Google Scholar
  59. D. Gumurdulu, A. Uguz, S. Erdogan, I. Tuncer, and O. Demircan, “Expression of c-erbB-2 oncoprotein in different types of thyroid tumors: an immunohistochemical study,” Endocrine Research, vol. 29, no. 4, pp. 465–472, 2003. View at Publisher · View at Google Scholar
  60. L. A. Akslen and J. E. Varhaug, “Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival,” Cancer, vol. 76, no. 9, pp. 1643–1654, 1995. View at Publisher · View at Google Scholar
  61. R. Kremser, P. Obrist, G. Spizzo et al., “Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease,” Virchows Archiv, vol. 442, no. 4, pp. 322–328, 2003. View at Google Scholar
  62. S. M. Wiseman, O. L. Griffith, A. Melck et al., “Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions,” The American Journal of Surgery, vol. 195, no. 5, pp. 667–673, 2008. View at Publisher · View at Google Scholar · View at PubMed
  63. S. Kato, T. Kobayashi, K. Yamada et al., “Expression of erbB receptors mRNA in thyroid tissues,” Biochimica et Biophysica Acta, vol. 1673, no. 3, pp. 194–200, 2004. View at Publisher · View at Google Scholar · View at PubMed
  64. D. R. F. Haugen, L. A. Akslen, J. E. Varhaug, and J. R. Lillehaug, “Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas,” Cancer Research, vol. 56, no. 6, pp. 1184–1188, 1996. View at Google Scholar
  65. A. Logan, C. Smith, G. P. Becks, A. M. Gonzalez, I. D. Phillips, and D. J. Hill, “Enhanced expression of transforming growth factor-β1 during thyroid hyperplasia in rats,” Journal of Endocrinology, vol. 141, no. 1, pp. 45–57, 1994. View at Google Scholar
  66. A. Coppa, G. Mincione, S. Mammarella, A. Ranieri, and G. Colletta, “Epithelial rat thyroid cell clones, escaping from transforming growth factor beta negative growth control, are still inhibited by this factor in the ability to trap iodide,” Cell Growth and Differentiation, vol. 6, no. 3, pp. 281–290, 1995. View at Google Scholar
  67. L. Attisano and J. L. Wrana, “Smads as transcriptional co-modulators,” Current Opinion in Cell Biology, vol. 12, no. 2, pp. 235–243, 2000. View at Publisher · View at Google Scholar
  68. T. Imamura, M. Takase, A. Nishihara et al., “Smad6 inhibits signalling by the TGF-beta superfamily,” Nature, vol. 389, no. 6651, pp. 622–626, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. A. Nakao, M. Afrakhte, A. Morén et al., “Identification of Smad7, a TGFbeta-inducible antagonist of TGFbeta signalling,” Nature, vol. 389, no. 6651, pp. 631–635, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. C. Suzuki, G. Murakami, M. Fukuchi et al., “Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane,” Journal of Biological Chemistry, vol. 277, no. 42, pp. 39919–39925, 2002. View at Publisher · View at Google Scholar · View at PubMed
  71. B. Grubeck-Loebenstein, G. Buchan, R. Sadeghi et al., “Transforming growth factor beta regulates thyroid growth. Role in the pathogenesis of nontoxic goiter,” Journal of Clinical Investigation, vol. 83, no. 3, pp. 764–770, 1989. View at Google Scholar
  72. F. Depoortere, I. Pirson, J. Bartek, J. E. Dumont, and P. P. Roger, “Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1),” Molecular Biology of the Cell, vol. 11, no. 3, pp. 1061–1076, 2000. View at Google Scholar · View at Scopus
  73. A. Franzén, E. Piek, B. Westermark, P. ten Dijke, and N.-E. Heldin, “Expression of transforming growth factor-beta1, activin A, and their receptors in thyroid follicle cells: negative regulation of thyrocyte growth and function,” Endocrinology, vol. 140, no. 9, pp. 4300–4310, 1999. View at Google Scholar
  74. C. Carneiro, C. V. Alvarez, J. Zalvide, A. Vidal, and F. Domínguez, “TGF-beta1 actions on FRTL-5 cells provide a model for the physiological regulation of thyroid growth,” Oncogene, vol. 16, no. 11, pp. 1455–1465, 1998. View at Google Scholar · View at Scopus
  75. X.-P. Pang, M. Park, and J. M. Hershman, “Transforming growth factor-beta blocks protein kinase-A-mediated iodide transport and protein kinase-C-mediated DNA synthesis in FRTL-5 rat thyroid cells,” Endocrinology, vol. 131, no. 1, pp. 45–50, 1992. View at Publisher · View at Google Scholar
  76. A. Kawaguchi, M. Ikeda, T. Endo, T. Kogai, A. Miyazaki, and T. Onaya, “Transforming growth factor-beta1 suppresses thyrotropin-induced Na+/I symporter messenger RNA and protein levels in FRTL-5 rat thyroid cells,” Thyroid, vol. 7, no. 5, pp. 789–794, 1997. View at Google Scholar
  77. A. E. Pekary and J. M. Hershman, “Tumor necrosis factor, ceramide, transforming growth factor-beta1, and aging reduce Na+/I symporter messenger ribonucleic acid levels in FRTL-5 cells,” Endocrinology, vol. 139, no. 2, pp. 703–712, 1998. View at Publisher · View at Google Scholar
  78. A. E. Pekary, S. R. Levin, D. G. Johnson, L. Berg, and J. M. Hershman, “Tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta 1 (TGF-beta 1) inhibit the expression and activity of Na+/K(+)-ATPase in FRTL-5 rat thyroid cells,” Journal of Interferon and Cytokine Research, vol. 17, no. 4, pp. 185–195, 1997. View at Google Scholar · View at Scopus
  79. M. Taton, F. Lamy, P. P. Roger, and J. E. Dumont, “General inhibition by transforming growth factor beta 1 of thyrotropin and cAMP responses in human thyroid cells in primary culture,” Molecular and Cellular Endocrinology, vol. 95, no. 1-2, pp. 13–21, 1993. View at Google Scholar
  80. D. Claisse, I. Martiny, B. Chaqour et al., “Influence of transforming growth factor beta1 (TGF-beta1) on the behaviour of porcine thyroid epithelial cells in primary culture through thrombospondin-1 synthesis,” Molecular and Cellular Endocrinology, vol. 112, part 9, pp. 1405–1416, 1999. View at Google Scholar
  81. H.-C. Kang, M. Ohmori, N. Harii, T. Endo, and T. Onaya, “Pax-8 is essential for regulation of the thyroglobulin gene by transforming growth factor-beta1,” Endocrinology, vol. 142, no. 1, pp. 267–275, 2001. View at Publisher · View at Google Scholar
  82. A. Nicolussi, S. D'Inzeo, M. Santulli, G. Colletta, and A. Coppa, “TGF-beta control of rat thyroid follicular cells differentiation,” Molecular and Cellular Endocrinology, vol. 207, no. 1-2, pp. 1–11, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. E. Costamagna, B. García, and P. Santisteban, “The functional interaction between the paired domain transcription factor Pax8 and Smad3 is involved in transforming growth factor-beta repression of the sodium/iodide symporter gene,” Journal of Biological Chemistry, vol. 279, no. 5, pp. 3439–3446, 2004. View at Publisher · View at Google Scholar · View at PubMed
  84. N. Delorme, C. Remond, H. Sartelet et al., “TGFbeta1 effects on functional activity of porcine thyroid cells cultured in suspension,” Journal of Endocrinology, vol. 173, no. 2, pp. 345–355, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. G. Kotlarz, Y. Wegrowski, L. Martiny, P. J. Declerck, and G. Bellon, “Enhanced expression of plasminogen activator inhibitor-1 by dedifferentiated thyrocytes,” Biochemical and Biophysical Research Communications, vol. 295, no. 3, pp. 737–743, 2002. View at Publisher · View at Google Scholar
  86. Y. Wegrowski, C. Perreau, L. Martiny, B. Haye, F. X. Maquart, and G. Bellon, “Transforming growth factor beta-1 up-regulates clusterin synthesis in thyroid epithelial cells,” Experimental Cell Research, vol. 247, no. 2, pp. 475–483, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. C. Garbi, G. Colletta, A. M. Cirafici, P. C. Marchisio, and L. Nitsch, “Transforming growth factor-beta induces cytoskeleton and extracellular matrix modifications in FRTL-5 thyroid epithelial cells,” European Journal of Cell Biology, vol. 53, no. 2, pp. 281–289, 1990. View at Google Scholar
  88. G. Napolitano, V. Montani, C. Giuliani et al., “Transforming growth factor-beta1 down-regulation of major histocompatibility complex class I in thyrocytes: coordinate regulation of two separate elements by thyroid-specific as well as ubiquitous transcription factors,” Molecular Endocrinology, vol. 14, no. 4, pp. 486–505, 2000. View at Publisher · View at Google Scholar
  89. M. Matsumura, N. Banba, S. Motohashi, and Y. Hattori, “Interleukin-6 and transforming growth factor-beta regulate the expression of monocyte chemoattractant protein-1 and colony-stimulating factors in human thyroid follicular cells,” Life Sciences, vol. 65, no. 12, pp. PL129–PL135, 1999. View at Publisher · View at Google Scholar
  90. Y.-C. L. Tseng, S. Lahiri, S. Jackson, K. D. Burman, and L. Wartofsky, “Endothelin binding to receptors and endothelin production by human thyroid follicular cells: effects of transforming growth factor-beta and thyrotropin,” Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 1, pp. 156–161, 1993. View at Publisher · View at Google Scholar
  91. M. J. Truty and R. Urrutia, “Basics of TGF-beta and pancreatic cancer,” Pancreatology, vol. 7, no. 5-6, pp. 423–435, 2007. View at Publisher · View at Google Scholar · View at PubMed
  92. J. Massagué, “TGFβ in cancer,” Cell, vol. 134, no. 2, pp. 215–230, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. L. Davies and H. G. Welch, “Increasing incidence of thyroid cancer in the United States, 1973–2002,” Journal of the American Medical Association, vol. 295, no. 18, pp. 2164–2167, 2006. View at Publisher · View at Google Scholar · View at PubMed
  94. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun, “Cancer statistics, 2007,” CA: A Cancer Journal for Clinicians, vol. 57, no. 1, pp. 43–66, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. V. Vasko, A. V. Espinosa, W. Scouten et al., “Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 8, pp. 2803–2808, 2007. View at Publisher · View at Google Scholar · View at PubMed
  96. S. P. Bidey, D. J. Hill, and M. C. Eggo, “Growth factors and goitrogenesis,” Journal of Endocrinology, vol. 160, no. 3, pp. 321–332, 1999. View at Google Scholar
  97. M. A. Pisarev, L. Thomasz, and G. J. Juvenal, “Role of transforming growth factor beta in the regulation of thyroid function and growth,” Thyroid, vol. 19, no. 8, pp. 881–892, 2009. View at Publisher · View at Google Scholar · View at PubMed
  98. D. Vesely, J. Astl, P. Lastuvka, P. Matucha, I. Sterzl, and J. Betka, “Serum levels of IGF-I, HGF, TGFbeta1, bFGF and VEGF in thyroid gland tumors,” Physiological Research, vol. 53, no. 1, pp. 83–89, 2004. View at Google Scholar · View at Scopus
  99. L. Levy and C. S. Hill, “Alterations in components of the TGF-beta superfamily signaling pathways in human cancer,” Cytokine and Growth Factor Reviews, vol. 17, no. 1-2, pp. 41–58, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  100. D. Lazzereschi, A. Ranieri, G. Mincione, S. Taccogna, F. Nardi, and G. Colletta, “Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein,” Cancer Research, vol. 57, no. 10, pp. 2071–2076, 1997. View at Google Scholar
  101. Y. Imamura, L. Jin, J. P. Grande et al., “Analysis of TGF-β and TGF-β-RII in thyroid neoplasms from the United States, Japan, and China,” Endocrine Pathology, vol. 9, no. 3, pp. 209–216, 1998. View at Google Scholar
  102. J. Seoane, “Escaping from the TGFbeta anti-proliferative control,” Carcinogenesis, vol. 27, no. 11, pp. 2148–2156, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. J. West, T. Munoz-Antonia, J. G. Johnson, D. Klotch, and C. A. Muro-Cacho, “Transforming growth factor-beta type II receptor and Smad proteins in follicular thyroid tumors,” Laryngoscope, vol. 110, no. 8, pp. 1323–1327, 2000. View at Google Scholar
  104. A. Turco, A. Coppa, S. Aloe et al., “Overexpression of transforming growth factor beta-type II receptor reduces tumorigenicity and metastastic potential of K-ras-transformed thyroid cells,” International Journal of Cancer, vol. 80, no. 1, pp. 85–91, 1999. View at Publisher · View at Google Scholar
  105. A. Nicolussi, S. D'Inzeo, A. Gismondi, and A. Coppa, “Reduction of invasive potential in K-ras-transformed thyroid cells by restoring of TGF-β pathway,” Clinical and Experimental Metastasis, vol. 23, no. 5-6, pp. 237–248, 2006. View at Publisher · View at Google Scholar · View at PubMed
  106. T. Hölting, A. Zielke, A. E. Siperstein, O. H. Clark, and Q.-Y. Duh, “Transforming growth factor-beta 1 is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion, and adhesion of cultured follicular and papillary thyroid cancer cell lines,” Journal of Clinical Endocrinology and Metabolism, vol. 79, no. 3, pp. 806–813, 1994. View at Publisher · View at Google Scholar
  107. S. E. Matsuo, S. G. Leoni, A. Colquhoun, and E. T. Kimura, “Transforming growth factor-beta1 and activin A generate antiproliferative signaling in thyroid cancer cells,” Journal of Endocrinology, vol. 190, no. 1, pp. 141–150, 2006. View at Publisher · View at Google Scholar · View at PubMed
  108. N. E. Heldin, D. Bergström, A. Hermansson et al., “Lack of responsiveness to TGF-beta1 in a thyroid carcinoma cell line with functional type I and type II TGF-beta receptors and Smad proteins, suggests a novel mechanism for TGF-beta insensitivity in carcinoma cells,” Molecular and Cellular Endocrinology, vol. 153, no. 1-2, pp. 79–90, 1999. View at Publisher · View at Google Scholar · View at Scopus
  109. D. Lazzereschi, F. Nardi, A. Turco et al., “A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours,” Oncogene, vol. 24, no. 34, pp. 5344–5354, 2005. View at Publisher · View at Google Scholar · View at PubMed
  110. S. D'Inzeo, A. Nicolussi, A. Ricci et al., “Role of reduced expression of SMAD4 in papillary thyroid carcinoma,” Journal of Molecular Endocrinology, vol. 45, no. 4, pp. 229–244, 2010. View at Publisher · View at Google Scholar · View at PubMed
  111. A. Moustakas and C. H. Heldin, “The regulation of TGFbeta signal transduction,” Development, vol. 136, no. 22, pp. 3699–3714, 2009. View at Google Scholar
  112. J. M. Cerutti, K. N. Ebina, S. E. Matsuo, L. Martins, R. M. B. Maciel, and E. T. Kimura, “Expression of Smad4 and Smad7 in human thyroid follicular carcinoma cell lines,” Journal of Endocrinological Investigation, vol. 26, no. 6, pp. 516–521, 2003. View at Google Scholar
  113. S. E. Matsuo, A. P. Z. Fiore, S. M. Siguematu et al., “Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues,” Arquivos Brasileiros de Endocrinologia & Metabologia, vol. 54, no. 4, pp. 406–412, 2010. View at Google Scholar
  114. D. Padua and J. Massagué, “Roles of TGFbeta in metastasis.,” Cell Research, vol. 19, no. 1, pp. 89–102, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  115. G. Riesco-Eizaguirre, I. Rodríguez, A. De La Vieja et al., “The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer,” Cancer Research, vol. 69, no. 21, pp. 8317–8325, 2009. View at Publisher · View at Google Scholar · View at PubMed
  116. R. Visone, P. Pallante, A. Vecchione et al., “Specific microRNAs are downregulated in human thyroid anaplastic carcinomas,” Oncogene, vol. 26, no. 54, pp. 7590–7595, 2007. View at Publisher · View at Google Scholar · View at PubMed
  117. J. Braun, C. Hoang-Vu, H. Dralle, and S. Hüttelmaier, “Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas,” Oncogene, vol. 29, no. 29, pp. 4237–4244, 2010. View at Publisher · View at Google Scholar · View at PubMed
  118. M. Ariga, T. Nedachi, M. Akahori et al., “Signalling pathways of insulin-like growth factor-I that are augmented by cAMP in FRTL-5 cells,” Biochemical Journal, vol. 348, part 2, pp. 409–416, 2000. View at Publisher · View at Google Scholar
  119. G. Mincione, D. L. Esposito, M. C. Di Marcantonio, A. Piccirelli, A. Cama, and G. Colletta, “TGF-β1 modulation of IGF-I signaling pathway in rat thyroid epithelial cells,” Experimental Cell Research, vol. 287, no. 2, pp. 411–423, 2003. View at Publisher · View at Google Scholar · View at Scopus
  120. A. B. Roberts and L. M. Wakefield, “The two faces of transforming growth factor β in carcinogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8621–8623, 2003. View at Publisher · View at Google Scholar · View at PubMed
  121. G. Torre-Amione, R. D. Beauchamp, H. Koeppen et al., “A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 4, pp. 1486–1490, 1990. View at Google Scholar
  122. M. P. De Caestecker, W. T. Parks, C. J. Frank et al., “Smad2 transduces common signals from receptor serinethreonine and tyrosine kinases,” Genes and Development, vol. 12, no. 11, pp. 1587–1592, 1998. View at Google Scholar
  123. M. Kretzschmar, J. Doody, and J. Massagué, “Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1,” Nature, vol. 389, no. 6651, pp. 618–622, 1997. View at Publisher · View at Google Scholar · View at PubMed
  124. M. Kretzschmar, J. Doody, I. Timokhina, and J. Massagué, “A mechanism of repression of TGFfβ/Smad signaling by oncogenic Ras,” Genes and Development, vol. 13, no. 7, pp. 804–816, 1999. View at Google Scholar
  125. M. M. Murillo, G. del Castillo, A. Sánchez, M. Fernández, and I. Fabregat, “Involvement of EGF receptor and c-Src in the survival signals induced by TGF-β1 in hepatocytes,” Oncogene, vol. 24, no. 28, pp. 4580–4587, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  126. G. del Castillo, M. M. Murillo, A. Alvarez-Barrientos et al., “Autocrine production of TGF-β confers resistance to apoptosis after an epithelial-mesenchymal transition process in hepatocytes: role of EGF receptor ligands,” Experimental Cell Research, vol. 312, no. 15, pp. 2860–2871, 2006. View at Publisher · View at Google Scholar · View at PubMed
  127. K. Song, T. L. Krebs, and D. Danielpour, “Novel permissive role of epidermal growth factor in transforming growth factor β (TGF-β) signaling and growth suppression. Mediation by stabilization of TGF-β receptor type II,” Journal of Biological Chemistry, vol. 281, no. 12, pp. 7765–7774, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  128. S. Uttamsingh, X. Bao, and K. T. Nguyen, “Synergistic effect between EGF and TGF-β1 in inducing oncogenic properties of intestinal epithelial cells,” Oncogene, vol. 27, no. 18, pp. 2626–2634, 2008. View at Google Scholar
  129. P. M. Siegel, W. Shu, R. D. Cardiff, W. J. Muller, and J. Massagué, “Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8430–8435, 2003. View at Publisher · View at Google Scholar · View at PubMed
  130. S. E. Seton-Rogers and J. S. Brugge, “ErbB2 and TGF-beta: a cooperative role in mammary tumor progression?” Cell Cycle, vol. 3, no. 5, pp. 597–600, 2004. View at Google Scholar · View at Scopus
  131. M. Andrianifahanana, M. C. Wilkes, C. E. Repellin et al., “ERBB receptor activation is required for profibrotic responses to transforming growth factor β,” Cancer Research, vol. 70, no. 19, pp. 7421–7430, 2010. View at Publisher · View at Google Scholar · View at PubMed
  132. G. Mincione, M. Cirafici, D. Lazzereschi, S. Pepe, F. Ciardiello, and G. Colletta, “Loss of thyrotropin regulation and transforming growth factor beta-induced growth arrest in erbB-2 overexpressing rat thyroid cells,” Cancer Research, vol. 53, no. 22, pp. 5548–5553, 1993. View at Google Scholar
  133. M. Nilsson, T. Dahlman, B. Westermark, and K. Westermark, “Transforming growth factor-β promotes epidermal growth factor-induced thyroid cell migration and follicle neoformation in collagen gel separable from cell proliferation,” Experimental Cell Research, vol. 220, no. 2, pp. 257–265, 1995. View at Publisher · View at Google Scholar · View at PubMed
  134. H. Mishima, M. Nakamura, J. Murakami, T. Nishida, and T. Otori, “Transforming growth factor-beta modulates effects of epidermal growth factor on corneal epithelial cells,” Current Eye Research, vol. 11, no. 7, pp. 691–696, 1992. View at Google Scholar
  135. S. Hoffmann, L. C. Hofbauer, V. Scharrenbach et al., “Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors,” Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 12, pp. 6139–6145, 2004. View at Google Scholar